

# Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

Bo Shen<sup>1#</sup>, Xiao Yi<sup>2,3#</sup>, Yaoting Sun<sup>2,3#</sup>, Xiaojie Bi<sup>1#</sup>, Juping Du<sup>1#</sup>, Chao Zhang<sup>4#</sup>, Sheng Quan<sup>4#</sup>, Fangfei Zhang<sup>2,3</sup>, Rui Sun<sup>2,3</sup>, Liuja Qian<sup>2,3</sup>, Weigang Ge<sup>2,3</sup>, Wei Liu<sup>2,3</sup>, Shuang Liang<sup>2,3</sup>, Hao Chen<sup>2,3</sup>, Ying Zhang<sup>1</sup>, Jun Li<sup>1</sup>, Jiaqin Xu<sup>1</sup>, Zebao He<sup>1</sup>, Baofu Chen<sup>1</sup>, Jing Wang<sup>1</sup>, Haixi Yan<sup>1</sup>, Yufen Zheng<sup>1</sup>, Donglian Wang<sup>1</sup>, Jiansheng Zhu<sup>1</sup>, Ziqing Kong<sup>4</sup>, Zhouyang Kang<sup>4</sup>, Xiao Liang<sup>2,3</sup>, Xuan Ding<sup>2,3</sup>, Guan Ruan<sup>2,3</sup>, Nan Xiang<sup>2,3</sup>, Xue Cai<sup>2,3</sup>, Huanhuan Gao<sup>2,3</sup>, Lu Li<sup>2,3</sup>, Sainan Li<sup>2,3</sup>, Qi Xiao<sup>2,3</sup>, Tian Lu<sup>2,3</sup>, Yi Zhu<sup>2,3\*</sup>, Huafen Liu<sup>4\*</sup>, Haixiao Chen<sup>1\*</sup>, Tiannan Guo<sup>2,3,5\*</sup>

<sup>1</sup>Taizhou Hospital, Wenzhou Medical University, 150 Ximen Street, Linhai 317000, Zhejiang Province, China;

<sup>2</sup>Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China;

<sup>3</sup>Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China;

<sup>4</sup>Calibra Lab at DIAN Diagnostics, 329 Jinpeng Street, Hangzhou 310030, Zhejiang Province, China;

<sup>5</sup>Lead Contact

# co-first;

\* Correspondence: [zhuyi@westlake.edu.cn](mailto:zhuyi@westlake.edu.cn) (Y.Z.); [liuhf1@dazd.cn](mailto:liuhf1@dazd.cn) (H.L.); [chenhx@enzemed.com](mailto:chenhx@enzemed.com) (H.C.); [guotiannan@westlake.edu.cn](mailto:guotiannan@westlake.edu.cn) (T.G.)

## SUMMARY

Severe COVID-19 patients account for most of the mortality of this disease. Early detection and effective treatment of severe patients remain major challenges. Here, we performed proteomic and metabolomic profiling of sera from 46 COVID-19 and 53 control individuals. We then trained a machine learning model using proteomic and metabolomic measurements from a training cohort of 18 non-severe and 13 severe patients. The model correctly classified severe patients with an accuracy of 93.5%, and was further validated using ten independent patients, seven of which were correctly classified. We identified molecular changes in the sera of COVID-19 patients implicating dysregulation of macrophage, platelet degranulation and complement system pathways, and massive metabolic suppression. This study shows that it is possible to predict progression to severe COVID-19 disease using serum protein and metabolite biomarkers. Our data also uncovered molecular pathophysiology of COVID-19 with potential for developing anti-viral therapies.

## 41 INTRODUCTION

42 Coronavirus disease 2019 (COVID-19) is an unprecedented global threat  
43 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It  
44 is currently spreading around the world rapidly. The sudden outbreak and  
45 accelerated spreading of SARS-CoV-2 infection have caused substantial  
46 public concerns. Within about two months, close to one million individuals  
47 worldwide have been infected, leading to about 50,000 deaths. At the time of  
48 writing this manuscript, about 100,000 new infections are reported daily.

49 Most COVID-19 studies have focused on its epidemiological and clinical  
50 characteristics (Ghinai et al., 2020; Guan et al., 2020; Li et al., 2020b; Team,  
51 2020). About 80% of patients infected with SARS-CoV-2 displayed mild  
52 symptoms with good prognosis (Team, 2020). They usually recover with, or  
53 even without, conventional medical treatment, and therefore are classified as  
54 mild or moderate COVID-19 (Medicine, 2020; Thevarajan et al., 2020).  
55 However, about 20% of patients suffer from respiratory distress and require  
56 immediate oxygen therapy or other inpatient interventions, including  
57 mechanical ventilation (Medicine, 2020; Murthy et al., 2020; Wu and  
58 McGoogan, 2020). These patients, classified as clinically severe or critical life-  
59 threatening infections, are mainly diagnosed empirically based on a set of  
60 clinical characteristics, such as respiratory rate ( $\geq 30$  times/min), mean  
61 oxygen saturation ( $\leq 93\%$  in the resting state) or arterial blood oxygen partial  
62 pressure/oxygen concentration ( $\leq 300$  mmHg) (Medicine, 2020). However,  
63 patients exhibiting these clinical manifestations have already progressed to a  
64 clinically severe phase and require immediate access to specialized intensive  
65 care; otherwise, they may die rapidly. Therefore, it is critical to develop new  
66 approaches to predict early which cases will likely become clinically severe. In  
67 addition, effective therapy for severe patients remains speculative, largely due  
68 to limited understanding of SARS-CoV-2 pathogenesis.

69 In this study, we hypothesized that SARS-CoV-2 induces characteristic  
70 molecular changes that can be detected in the sera of severe patients. These  
71 molecular changes may shed light on therapy development for COVID-19  
72 patients. To test this hypothesis, we applied cutting-edge proteomic  
73 (Aebersold and Mann, 2016; Li et al., 2020a) and metabolomic (Hou et al.,  
74 2020; Lee et al., 2019) technologies to analyze the proteome and  
75 metabolome of sera from severe COVID-19 patients and several control  
76 groups.

77

## 78 RESULTS

### 79 Proteomic and metabolomic profiling of COVID-19 sera

80 We procured a cohort of patients (Zheng et al., 2020) containing 21  
81 severe COVID-19 patients, in which 11 sera from severe patients were  
82 collected one to six days before the patients were clinically assessed as

83 severe. Sera from the remaining eight patients were collected within about 3  
84 days after diagnosed as severe cases (Figure 1A, Table 1, Table S1). Controls  
85 with matched epidemiological features were included to identify severity-  
86 related molecular alterations. These controls were 28 healthy subjects, 25  
87 non-COVID-19 patients (negative for the SARS-CoV-2 nucleic acid test) with  
88 similar clinical characteristics as COVID-19 patients, and 25 non-severe  
89 COVID-19 patients. A serum sample was obtained from each patient within a  
90 few days after hospital admission, with a few exceptions when samplings  
91 were performed at later disease stages.

92 We used stable isotope labeled proteomics strategy TMTpro (16plex) (Li  
93 et al., 2020a) and UPLC-MS/MS untargeted metabolomics approach to  
94 analyze 92 undepleted sera from 86 individuals. Altogether 894 proteins were  
95 quantified and 941 (including 36 drugs and their metabolites) metabolites  
96 were identified with authentic compound library searching. For metabolomic  
97 analysis, both hydrophilic and hydrophobic molecules were analyzed using  
98 both positive and negative ionization to cover various endogenous  
99 biochemical classes. Our data were acquired with high degree of consistency  
100 and reproducibility. In quality control analysis, the median coefficient of  
101 variance (CV) values for proteomic and metabolomic data were 10% and 5%,  
102 respectively (Figure S1A). Remarkably, sera from SARS-CoV-2 infected  
103 patients were well resolved from healthy individuals, and the sera from severe  
104 patients displayed distinct proteomic and metabolomic patterns compared to  
105 those from other groups (Figures S1B-C).

106

### 107 **Identification of severe patients using machine learning**

108 We next investigated the possibility of classify the severe COVID-19  
109 patients based on the molecular signatures of proteins and metabolites (Table  
110 S2). We built a random forest machine learning model based on proteomic  
111 and metabolomic data from 18 non-severe and 13 severe patients (Figure  
112 1B), leading to prioritization of 29 important variables including 22 proteins  
113 and 7 metabolites (Figure 2A-B). This model reached an AUC of 0.957 in the  
114 training set (Figure 2C). One non-severe patient, XG3, was incorrectly  
115 classified as severe (Figure 2D), possibly because this 70-year-old male  
116 patient was the oldest individual in this cohort (Figure 1A). For patient XG40,  
117 the reason of incorrectly classified is unclear.

118 We then tested the model on an independent cohort of ten patients  
119 (Figure 2E, Table S3). All severe patients were correctly identified, except one  
120 patient, XG45, a 62-year-old male who had received traditional Chinese  
121 medicines during more than 20 days before admission. This individual was  
122 the patient with the longest pre-admission treatment in this cohort and the  
123 administration of traditional Chinese medicines might have also accounted for  
124 the incorrect prediction. Another incorrectly classified non-severe patient was  
125 XG22, a 43 year-old male with chronic HBV infection and diabetes who had  
126 the longest hospitalization (>50 days) among all non-severe patients. Indeed,

127 our molecular-based prediction flagged him as an outlier, suggesting that his  
128 prolonged treatment history might have interfered with the expression of the  
129 panel of the 29 variables. For reasons yet unclear, XG25, a 43-year-old male  
130 non-severe case, was incorrectly classified as severe.

131

### 132 **Proteomic and metabolomic changes in severe COVID-19 sera**

133 We found that 105 proteins were differentially expressed in COVID-19  
134 patients, but not in the non-COVID-19 patients (Figure S2, S4). After  
135 correlating their expression with clinical disease severity (Figure S5), 93  
136 proteins showed specific modulation in severe patients. Pathway analysis and  
137 network enrichment analyses of the 93 differentially expressed proteins  
138 revealed three pathways (Figure S6), namely activation of the complement  
139 system, macrophage function and platelet degranulation, involving 50 proteins  
140 (Figure 3A) in the sera of severe patients. Similarly, 373 and 204 metabolites  
141 were found with differential abundance in COVID-19 patients and continually  
142 changed correlated with disease severity in our metabolomics data,  
143 respectively (Figure S3, S4). Correspondingly, 82 metabolites were involved  
144 in the three biological processes. We summarize the key dysregulated  
145 molecules in Figure 5 and discussed in the following sections.

146

### 147 **Dysregulated macrophage and lipid metabolism**

148 Our data uncovered dysregulation of multiple apolipoproteins including  
149 APOA1, APOA2, APOH, APOL1, APOD and APOM (Figure 3A). Most of them  
150 are associated with macrophage function and were down-regulated. Decrease  
151 of APOA1 in serum has been reported during the transition of COVID-19  
152 patients from mild to severe illness (Nie et al., 2020). The APOM in serum of  
153 severe patients was downregulated compared with healthy and non-severe  
154 COVID-19 patients. Regulation of serum APOM has also been observed in  
155 hepatitis B virus (HBV) patients (Gu et al., 2011).

156 Consistent with these proteomic findings, we also detected dysregulated  
157 metabolites involved in lipid metabolism. Accumulation of 16 steroid hormones  
158 in COVID-19 patients may contribute to macrophage modulation. Steroid  
159 hormones, including progesterone, androgens, estrogens and bile acids can  
160 promote the activity of macrophages (Vernon-Roberts, 1969). Specifically,  
161 glucocorticoids were recently reported to be clinically efficacious (Wang et al.,  
162 2020b). We detected increased 21-hydroxypregnenolone, the essential  
163 intermediate for synthesizing corticosterone, suggesting that corticosterone  
164 biosynthesis may be a protective mechanism against SARS-CoV-2 infection.

165 We also found evidence of significant activation of the kynurenine  
166 pathway. Metabolites of kynurenate, kynurenine, 8-methoxykynurenate were  
167 enriched in COVID-19 patients. Nicotinamide adenine dinucleotide (NAD+),  
168 the cofactor in many cellular redox reactions, can be synthesized from  
169 tryptophan by the kynurenine pathway and operates as a switch for  
170 macrophage effector responses (Minhas et al., 2019).

171 The macrophage process is closely related to lipid metabolism. Over 100  
172 lipids were down-regulated in severe patients. Our data showed decreased  
173 sphingolipids in both non-severe and severe COVID-19 patients (Figure 4A).  
174 Sphingolipids and glycerophospholipids are important components of  
175 biomembranes, which mediate signal transduction and immune activation  
176 processes. Sphingolipids, such as sphingosine-1-phosphate, can induce  
177 macrophage activation, inhibit macrophage apoptosis, and promote migration  
178 of macrophages to inflammatory sites (Weigert et al., 2009). Phagocytosis  
179 and platelet degranulation are coupled with changes in biomembrane lipid  
180 composition and fluidity, and modulate the production of glycerophospholipids  
181 (Rouzer et al., 2007). In this study, we found continuous decrease of  
182 glycerophospholipids after SARS-CoV-2 infection. Glycerophospholipids and  
183 fatty acids such as arachidonic acid have been found significantly elevated in  
184 HCoV-229E-infected cells, and exogenous supplement of arachidonic acid  
185 significantly suppressed HCoV-229E and MERS-CoV replication (Yan et al.,  
186 2019). Our data suggest severe COVID-19 patients might benefit from this  
187 therapeutical strategy as well.

188 Choline and its derivatives were down-regulated in COVID-19 patients,  
189 particularly in severe cases; phosphocholine, the intermediate product for  
190 producing phosphatidylcholine (PC) was up-regulated (Figure 4B). This was  
191 probably due to activated macrophage-mediated immunity (Sanchez-Lopez et  
192 al., 2019). Polarization of macrophages in response to pathogens requires  
193 increased absorption of choline for PC formation, thereby promoting cytokine  
194 secretion (Sanchez-Lopez et al., 2019).

195

### 196 **Activated acute phase proteins (APPs) and the complement system**

197 We detected 10 APPs among 20 proteins that are differentially expressed  
198 between non-severe and severe groups (Figure 2A). They are involved at the  
199 early stages of immune responses to virus infection. Among the most  
200 significantly upregulated in severe sera were APPs, including serum amyloid  
201 A-1 (SAA1), serum amyloid A-2 (SAA2), serum amyloid A-4 (SAA4), C-  
202 reactive protein (CRP), alpha-1-antichymotrypsin (SERPINA3) and serum  
203 amyloid P-component (SAP/APCS) (Figure 3B). Some of them are known to  
204 be biomarkers for viral infections, including SAA1, SAA2 and CRP. While  
205 CRP has been associated with COVID-19, the other proteins have not  
206 previously been reported in COVID-19 (Liang et al., 2020). SAA1 was  
207 reported to be elevated in severe SARS patients, but was not specific to  
208 SARC-CoV (Pang et al., 2006). As a major contributor to acute phase  
209 response, complement system plays a crucial role in eliminating invading  
210 pathogens in the early stage of infection. Among those APPs, two proteins  
211 belong to the complement membrane attack complex, including complement 6  
212 (C6) and complement factor B (CFB). Two other proteins, Properdin (CFP)  
213 and Carboxypeptidase N catalytic chain (CPN1), are regulators of  
214 complement system (Figure 3).

215 We also observed an accumulation of mannose and its derivatives in  
216 severe patients. In the complement system, binding of mannose to lectin  
217 leads to cleavage of C2 and C4, which then form a C3 convertase to  
218 promote complement activation (Ricklin et al., 2010).

219

### 220 **Suppressed platelet degranulation in severe sera**

221 Fifteen of 17 proteins involved in platelet degranulation were down-  
222 regulated in SARS-CoV-2 infected patients, which may be associated with  
223 observed thrombocytopenia in this patient cohort (Zheng et al., 2020). Low  
224 platelet count is also reported to be associated with severe COVID-19 and  
225 mortality (Lippi et al., 2020). Two of the most intriguing proteins down-  
226 regulated in severe patients are platelet expressing chemokines pro-platelet  
227 basic protein (PPBP; also called macrophage-derived growth factor) and  
228 platelet factor 4 (PF4). PF-4 was identified as a broad-spectrum HIV-1  
229 inhibitor at the level of virus attachment and entry via interaction with the  
230 major viral envelope glycoprotein gp120 (Auerbach et al., 2012). In another  
231 sera proteomic investigation of SARS, they found decreasing PF4 was  
232 associated with poor prognosis (Poon et al., 2012), in consistent with our  
233 findings regarding COVID-19.

234 Most enterochromaffin cell-derived serotonin (5-hydroxytryptamine [5-  
235 HT]) are transported to platelets for storage and release (Baganz and Blakely,  
236 2013). Our previous data showed that when platelet counts in COVID-19  
237 patients decrease as the severity of the disease increase (Zheng et al., 2020),  
238 serotonin (Figure 4B) level decreases accordingly. Compared with the healthy  
239 group, serotonin in non-severe and severe COVID-19 patients decreased by  
240 2.07-fold ( $p = 1.86e-04$ ) and 3.31-fold ( $p = 9.07e-07$ ), respectively.

241 We also detected low levels of fatty acids such as arachidonate and  
242 docosapentaenoate in COVID-19 patients (Figure 4), which may be related to  
243 their decreased platelet counts. Fatty acids including arachidonate (20:4n6)  
244 are active factors of platelet degranulation. A study on H7N9 reported that  
245 H7N9 infection led to suppression of various fatty acids including palmitic acid  
246 (Sun et al., 2018). We also found palmitic acid decreased in severe COVID-19  
247 patients.

248

### 249 **Massive suppression of amino acids in the sera of COVID-19 patients**

250 More than 100 decreased metabolites in the sera of COVID-19 patients  
251 are amino acids and their derivatives were found significantly decreased in the  
252 sera of COVID-19 patients compared to their levels in the healthy controls,  
253 while their levels were either unchanged or even increased in the sera of non-  
254 COVID-19 patients. Enriched in these metabolites are ten metabolites  
255 involved in arginine metabolism including glutamate, arginine, N-(l-  
256 arginino)succinate, citrulline, ornithine, glutamine, 2-oxoglutarate, N-acetyl-L-  
257 glutamate, urea, and fumarate. In addition, some arginine derivatives such as  
258 argininate, asymmetric dimethylarginine, symmetric dimethylarginine,

259 homoarginine and N-acetylarginine, were also significantly decreased in the  
260 sera of non-severe COVID-19 patients. It has been reported that arginine  
261 metabolism is suppressed in severe fever with thrombocytopenia syndrome  
262 caused by a SFTS bunyavirus (SFTSV)(Li et al., 2018b). Decreased arginine  
263 levels in SFTSV patients was associated with impaired anti-SFTSV functions  
264 of T cells.  
265

## 266 **DISCUSSION**

### 267 **Prediction of severe COVID-19 patients**

268 Although COVID-19 can be diagnosed effectively by nucleic acid-based  
269 methods at an early stage, it is equally critical to identify severe COVID-19  
270 patients before their manifestation of severe symptoms to minimize mortality. In  
271 this study we show that severe cases can be predicted by molecular  
272 signatures of metabolites and proteins using a machine learning model based  
273 on the expression levels of 22 serum proteins and seven metabolites (Figure  
274 2A-B). We achieved an overall accuracy of 93.5% in the training set.  
275 Prediction of two patients did not match clinical diagnosis. One of them is non-  
276 severe individual who was the oldest patient in the training cohort.  
277 Remarkably, nine severe patients were correctly identified retrospectively  
278 based on the analysis of their sera collected one to six days before they were  
279 clinically diagnosed as having deteriorated to a severe state (Figure 1, Figure  
280 2D), suggesting that their sera protein and metabolite signatures at the  
281 sampling time were already pointing to further deterioration into severe state  
282 even when severe clinical symptoms have not started to appear yet.

283 The proteins and metabolites used in our classifier (Figure 2A) contain  
284 several known biomarkers for viral infections, such as SAA2, SSA1 and CRP,  
285 which have already been used empirically to monitor the severity of COVID-  
286 19. Our study suggests that more characteristic molecular changes at protein  
287 and metabolite levels can be used to build a predictive model for the  
288 prospective identification of severe cases. The classifier also included  
289 exceptionally high levels of other acute phase proteins, including SERPINA3,  
290 among others (Figure 2A-B). Our data suggest potential benefits of broader  
291 testing of these proteins in newly diagnosed cases to identify which COVID-19  
292 patients are likely to progress to severe disease. The model contains  
293 molecules involved in hepatic damage. The elevation of glucose, glucuronate,  
294 bilirubin degradation product and four bile acid derivatives, suggests  
295 suppressed hepatic detoxification (Rowland et al., 2013). Vascular cell  
296 adhesion protein 1 (VCAM-1) which helps to regulate transendothelial  
297 migration of leukocytes by stimulating production of reactive oxygen species  
298 (ROS), was upregulated in our data. As a potent antioxidant and inhibitor of  
299 VCAM-1 dependent cellular events (Keshavan et al., 2005), bilirubin was  
300 found to be down-regulated in our metabolomic data.

301 Seven patients were correctly classified in the independent validation  
302 cohort containing ten patients. Two of them could be explained by the  
303 patients' complex comorbidity and medication history. The relatively small  
304 sample size necessitates future validation studies in independent cohorts.

305

### 306 **Molecular insights for pathogenesis of SARS-CoV-2 infection**

307 Our data shed light on the molecular changes reflected in COVID-19 sera  
308 which could potentially yield critical diagnostic markers or therapeutic targets  
309 for managing severe COVID-19 patients (Figure 5). These molecular  
310 derangements may originate from binding of SARS-CoV-2 to alveolar  
311 macrophages via the ACE2 receptor (Hoffmann et al., 2020), resulting in  
312 release of IL-6 and TNF- $\alpha$  (Mehta et al., 2020) by macrophages (Gabay and  
313 Kushner, 1999). In response to elevated cytokines, especially IL-6 which  
314 triggers fever, the liver releases various APPs. Activation of APPs is  
315 accompanied with the immunogenesis or organic damage (Gabay and  
316 Kushner, 1999). Our metabolomics data also provide plausible evidence for  
317 hepatic injury. In physiological condition, hormone or bilirubin binds to  
318 glucuronate, a derivative of glucose, for liver detoxification (Rowland et al.,  
319 2013). The elevation of glucose, glucuronate, bilirubin degradation product  
320 and four bile acid derivatives in severe patients, indicating the potential  
321 declined detoxification function (Figures 4-5). Indeed, our data showed an  
322 upregulation of multiple APPs, including CRP and major attack complexes  
323 (MACs) in the severe sera. CRP can activate the complement system (Chirco  
324 and Potempa, 2018). This on the one hand leads to enhanced cytokine and  
325 chemokine production, potentially contributing to "cytokine storm"; and on the  
326 other overly recruits macrophages from the peripheral blood, which could  
327 result in acute lung injury (Chirco and Potempa, 2018; Narasaraju et al., 2011).  
328 Because about 50% of platelets are produced in the lung (Lefrancais et al.,  
329 2017), platelet may in turn respond to lung injury and activate macrophases  
330 by degranulation (Mantovani and Garlanda, 2013), which may further add to  
331 "cytokine storm". A recent necropsy report revealed alveolar macrophage  
332 infiltration and activation in severe COVID-19 patients (Liao M., 2020),  
333 supporting our findings.

334

### 335 **Insights for COVID-19 therapeutics**

336 To date, few other therapies are proven effective for severe COVID-19  
337 patients. Most of patients receive standard supportive care and antiviral  
338 therapy (Wang et al., 2020a). Corticosteroid treatment which are effectively in  
339 suppressing MERS-CoV and SARS-CoV (Arabi et al., 2018), but showed  
340 negligible effect on COVID-19 patients and may even have induced lung  
341 injury (Russell et al., 2020). The molecular changes revealed in this study in  
342 the COVID-19 sera have allowed us to propose potential new therapeutic  
343 strategies for the severe patients.



344 Our proteomic data showed that proteins related to platelet degranulation  
345 were substantially down-regulated in severe patients, a finding which was  
346 confirmed by low platelet counts (Zheng et al., 2020). The association  
347 between thrombocytopenia and viral infection has been observed in SARS-  
348 CoV (Zou et al., 2004), hepatitis C virus (HCV) (Assinger, 2014), and Dengue  
349 virus (Wilder-Smith et al., 2004). We thus recommend watching closely  
350 monitoring changes in platelets and making interventions, such as infusions of  
351 thrombopoietin (TPO) as necessary, particularly when liver or kidney injuries  
352 occur.

353 Complement activation suppresses virus invasion, and may lead to  
354 inflammatory syndromes (Barnum, 2016). Our data showed a general up-  
355 regulation of complement system proteins, including MAC proteins such as  
356 C5, C6 and C8. Suppression of complement system has been reported as an  
357 effective immunotherapeutics in SARS-infected mouse model (Gralinski et al.,  
358 2018). C5a has been reported as highly expressed in severe SARS and  
359 MERS patients as well (Wang et al., 2015). Inhibition of C5a has been  
360 reported to alleviate viral infection-induced acute lung injury (Garcia et al.,  
361 2013; Jiang et al., 2018; Sun et al., 2014). Our data suggest that severe  
362 COVID-19 patients might benefit from suppression of complement system.

363 The coronavirus are enveloped, positive strand RNA viruses, the  
364 replication and assembly of which consume large amount of lipids. Our  
365 metabolomics results showed that more than 100 lipids including  
366 glycerophospholipid, sphingolipids and fatty acids were down-regulated in  
367 COVID-19 patients sera, probably due to rapid replication of the virus.  
368 Glycerophospholipid, sphingolipids (one of the components of lipid rafts) and  
369 fatty acids have been reported to play an important role in the early  
370 development of enveloped viruses (Schoggins and Randall, 2013).  
371 Suppression of cholesterol synthesis by M $\beta$ CD has been reported inhibiting  
372 the production of SARS-CoV particles released from infected Vero E6 cells (Li  
373 et al., 2007). Drugs inhibiting lipid synthesis such as statin have been  
374 proposed to treat HCV (Heaton and Randall, 2011) and COVID-19 (Fedson et  
375 al., 2020). Our data also supports this potential therapeutics for severe  
376 COVID-19 patients.

377 SARS-CoV-2 is highly infectious, applying huge pressure to the medical  
378 system worldwide. Upon COVID-19 outbreak, limited information of this  
379 pathogen was available, which restricted the collection of clinical specimens  
380 for this study. The reason for the small sample size of this study were  
381 biosafety constraints.

382 In conclusion, this study presents a systematic proteomic and metabolomic  
383 investigation of sera from multiple COVID-19 patient groups and control  
384 groups. We show that feasibility of predicting severe COVID-19 patients  
385 based on a panel of serum proteins and metabolites. Our data offer a  
386 landscape of blood molecular changes induced by SARS-CoV-2 infection,  
387 which may provide useful diagnostic markers and therapeutic targets.

388

389

## 390 **ACKNOWLEDGEMENTS**

391 This work is supported by grants from Westlake Special Program for COVID-  
392 19 (2020), and Tencent foundation (2020), National Natural Science  
393 Foundation of China (81972492, 21904107, 81672086), Zhejiang Provincial  
394 Natural Science Foundation for Distinguished Young Scholars  
395 (LR19C050001), Hangzhou Agriculture and Society Advancement Program  
396 (20190101A04). We thank Drs. R. Aeberold, O.L. Kon, H. Yu, D. Li, and the  
397 Guomics team for invaluable comments to this study. We thank Westlake  
398 University Supercomputer Center for assistance in data storage and  
399 computation.

## 400 **AUTHOR CONTRIBUTIONS**

401 T.G., H.C., H.L., B.S. and Y.Z. designed and supervised the project. B.S.,  
402 X.B., J.D., Y.Z., J.L., J.X., Z.H., B.C., J.W., H.Y., Y.Z., D.W. and J.Z. collected  
403 the samples and clinical data. X.Y., Y.S., F.Z., R.S., L.Q., W.G., W.L., S.L.,  
404 H.C., X.L., X.D., G.R., N.X., X.C., H.G., L.L., S.L., Q.X. and T.L. conducted  
405 proteomic analysis. Data were interpreted and presented by all co-authors.  
406 C.Z., S.Q., Z.K. and Z.K. conducted metabolomic analysis. T.G. wrote the  
407 manuscript with inputs from co-authors.

## 408 **DECLARATION OF INTERESTS**

409 The research group of T.G. is partly supported by Tencent, Thermo Fisher  
410 Scientific, SCIEX and Pressure Biosciences Inc. C.Z., Z.K., Z.K. and S.Q. are  
411 employees of DIAN Diagnostics.

## 412 **DATA AVAILABILITY**

413 All data are available in the manuscript or the supplementary material. The  
414 proteomics and metabolomics data are deposited in ProteomeXchange  
415 Consortium (<https://www.iprox.org/>). Project ID: IPX0002106000. All the data  
416 will be publicly released upon publication.

## 417 **REFERENCES**

- 418 Aebersold, R., and Mann, M. (2016). Mass-spectrometric exploration of proteome structure and  
419 function. *Nature* *537*, 347-355.
- 420 Arabi, Y.M., Mandourah, Y., Al-Hameed, F., Sindi, A.A., Almekhlafi, G.A., Hussein, M.A., Jose, J.,  
421 Pinto, R., Al-Omari, A., Kharaba, A., *et al.* (2018). Corticosteroid Therapy for Critically Ill Patients  
422 with Middle East Respiratory Syndrome. *Am J Respir Crit Care Med* *197*, 757-767.
- 423 Assinger, A. (2014). Platelets and infection - an emerging role of platelets in viral infection. *Front*  
424 *Immunol* *5*, 649.
- 425 Auerbach, D.J., Lin, Y., Miao, H., Cimbro, R., Difiore, M.J., Gianolini, M.E., Furci, L., Biswas, P., Fauci,  
426 A.S., and Lusso, P. (2012). Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-

## Molecular profiling of COVID-19 sera

- 427 spectrum HIV-1 inhibitor. *Proc Natl Acad Sci U S A* *109*, 9569-9574.
- 428 Baganz, N.L., and Blakely, R.D. (2013). A dialogue between the immune system and brain, spoken  
429 in the language of serotonin. *ACS Chem Neurosci* *4*, 48-63.
- 430 Barnum, S. (2016). Complement: A Primer for the Coming Therapeutic Revolution. *Pharmacology  
431 & Therapeutics* *172*.
- 432 Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.H., Pages,  
433 F., Trajanoski, Z., and Galon, J. (2009). ClueGO: a Cytoscape plug-in to decipher functionally  
434 grouped gene ontology and pathway annotation networks. *Bioinformatics* *25*, 1091-1093.
- 435 Chirco, K.R., and Potempa, L.A. (2018). C-Reactive Protein As a Mediator of Complement Activation  
436 and Inflammatory Signaling in Age-Related Macular Degeneration. *Frontiers in Immunology* *9*,  
437 539.
- 438 Fedson, D.S., Opal, S.M., and Rordam, O.M. (2020). Hiding in Plain Sight: an Approach to Treating  
439 Patients with Severe COVID-19 Infection. *mBio* *11*.
- 440 Gabay, C., and Kushner, I. (1999). Acute-Phase Proteins and Other Systemic Responses to  
441 Inflammation. *New England Journal of Medicine* *340*, 448-454.
- 442 Gao, H., Zhang, F., Liang, S., Zhang, Q., Lyu, M., Qian, L., Liu, W., Ge, W., Chen, C., Yi, X., *et al.* (2020).  
443 Accelerated Lysis and Proteolytic Digestion of Biopsy-Level Fresh-Frozen and FFPE Tissue Samples  
444 Using Pressure Cycling Technology. *Journal of Proteome Research*.
- 445 Garcia, C.C., Weston-Davies, W., Russo, R.C., Tavares, L.P., Rachid, M.A., Alves-Filho, J.C., Machado,  
446 A.V., Ryffel, B., Nunn, M.A., and Teixeira, M.M. (2013). Complement C5 activation during influenza  
447 A infection in mice contributes to neutrophil recruitment and lung injury. *PLoS One* *8*, e64443-  
448 e64443.
- 449 Ghinai, I., McPherson, T.D., Hunter, J.C., Kirking, H.L., Christiansen, D., Joshi, K., Rubin, R., Morales-  
450 Estrada, S., Black, S.R., Pacilli, M., *et al.* (2020). First known person-to-person transmission of severe  
451 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. *The Lancet*.
- 452 Gralinski, L.E., Sheahan, T.P., Morrison, T.E., Menachery, V.D., Jensen, K., Leist, S.R., Whitmore, A.,  
453 Heise, M.T., and Baric, R.S. (2018). Complement Activation Contributes to Severe Acute Respiratory  
454 Syndrome Coronavirus Pathogenesis. *mBio* *9*, e01753-01718.
- 455 Gu, J.-G., Zhu, C.-l., Cheng, D.-z., Xie, Y., Liu, F., and Zhou, X. (2011). Enhanced levels of  
456 apolipoprotein M during HBV infection feedback suppresses HBV replication. *Lipids Health Dis* *10*,  
457 154-154.
- 458 Guan, W.-j., Ni, Z.-y., Hu, Y., Liang, W.-h., Ou, C.-q., He, J.-x., Liu, L., Shan, H., Lei, C.-l., Hui, D.S.C.,  
459 *et al.* (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of  
460 Medicine*.
- 461 Heaton, N.S., and Randall, G. (2011). Multifaceted roles for lipids in viral infection. *Trends Microbiol*  
462 *19*, 368-375.
- 463 Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T.S.,  
464 Herrler, G., Wu, N.H., Nitsche, A., *et al.* (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and  
465 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*.
- 466 Hou, Y.C., Yu, H.C., Martin, R., Cirulli, E.T., Schenker-Ahmed, N.M., Hicks, M., Cohen, I.V., Jonsson,  
467 T.J., Heister, R., Napier, L., *et al.* (2020). Precision medicine integrating whole-genome sequencing,  
468 comprehensive metabolomics, and advanced imaging. *Proc Natl Acad Sci U S A* *117*, 3053-3062.
- 469 Jiang, Y., Zhao, G., Song, N., Li, P., Chen, Y., Guo, Y., Li, J., Du, L., Jiang, S., Guo, R., *et al.* (2018).  
470 Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with

## Molecular profiling of COVID-19 sera

- 471 MERS-CoV. *Emerg Microbes Infect* *7*, 77-77.
- 472 Keshavan, P., Deem, T.L., Schwemberger, S.J., Babcock, G.F., Cook-Mills, J.M., and Zucker, S.D.  
473 (2005). Unconjugated bilirubin inhibits VCAM-1-mediated transendothelial leukocyte migration. *J*  
474 *Immunol* *174*, 3709-3718.
- 475 Kramer, A., Green, J., Pollard, J., Jr., and Tugendreich, S. (2014). Causal analysis approaches in  
476 Ingenuity Pathway Analysis. *Bioinformatics* *30*, 523-530.
- 477 Lee, A.H., Shannon, C.P., Amenyogbe, N., Bennike, T.B., Diray-Arce, J., Idoko, O.T., Gill, E.E., Ben-  
478 Othman, R., Pomat, W.S., van Haren, S.D., *et al.* (2019). Dynamic molecular changes during the first  
479 week of human life follow a robust developmental trajectory. *Nat Commun* *10*, 1092.
- 480 Lefrancais, E., Ortiz-Munoz, G., Caudrillier, A., Mallavia, B., Liu, F., Sayah, D.M., Thornton, E.E.,  
481 Headley, M.B., David, T., Coughlin, S.R., *et al.* (2017). The lung is a site of platelet biogenesis and a  
482 reservoir for haematopoietic progenitors. *Nature* *544*, 105-109.
- 483 Li, G.M., Li, Y.G., Yamate, M., Li, S.M., and Ikuta, K. (2007). Lipid rafts play an important role in the  
484 early stage of severe acute respiratory syndrome-coronavirus life cycle. *Microbes Infect* *9*, 96-102.
- 485 Li, J., Van Vranken, J.G., Pontano Vaites, L., Schweppe, D.K., Huttlin, E.L., Etienne, C., Nandhikonda,  
486 P., Viner, R., Robitaille, A.M., Thompson, A.H., *et al.* (2020a). TMTpro reagents: a set of isobaric  
487 labeling mass tags enables simultaneous proteome-wide measurements across 16 samples. *Nat*  
488 *Methods*.
- 489 Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K.S.M., Lau, E.H.Y., Wong, J.Y.,  
490 *et al.* (2020b). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected  
491 Pneumonia. *N Engl J Med*.
- 492 Li, T., Kim, A., Rosenbluh, J., Horn, H., Greenfeld, L., An, D., Zimmer, A., Liberzon, A., Bistline, J.,  
493 Natoli, T., *et al.* (2018a). GeNets: a unified web platform for network-based genomic analyses. *Nat*  
494 *Methods* *15*, 543-546.
- 495 Li, X.K., Lu, Q.B., Chen, W.W., Xu, W., Liu, R., Zhang, S.F., Du, J., Li, H., Yao, K., Zhai, D., *et al.* (2018b).  
496 Arginine deficiency is involved in thrombocytopenia and immunosuppression in severe fever with  
497 thrombocytopenia syndrome. *Sci Transl Med* *10*.
- 498 Liang, T., Cai, H., Chen, Y., Chen, Z., Fang, Q., Han, W., Hu, S., Li, J., Li, T., Lu, X., *et al.* (2020).  
499 Handbook of COVID-19 Prevention and Treatment
- 500 Liao M., e.a. (2020). The landscape of lung bronchoalveolar immune cells in COVID-19 revealed  
501 by single-cell RNA sequencing. medRxiv, <https://doi.org/10.1101/2020.1102.1123.20026690>.
- 502 Lippi, G., Plebani, M., and Henry, B.M. (2020). Thrombocytopenia is associated with severe  
503 coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta* *506*, 145-148.
- 504 Mantovani, A., and Garlanda, C. (2013). Platelet-macrophage partnership in innate immunity and  
505 inflammation. *Nat Immunol* *14*, 768-770.
- 506 Medicine, N.H.C.o.t.P.s.R.o.C.a.N.A.o.T.C. (2020). Chinese Government Diagnosis and Treatment  
507 Guideline (Trial 5th version).
- 508 Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., Manson, J.J., and Hlh Across  
509 Speciality Collaboration, U.K. (2020). COVID-19: consider cytokine storm syndromes and  
510 immunosuppression. *Lancet* *395*, 1033-1034.
- 511 Minhas, P.S., Liu, L., Moon, P.K., Joshi, A.U., Dove, C., Mhatre, S., Contrepois, K., Wang, Q., Lee, B.A.,  
512 Coronado, M., *et al.* (2019). Macrophage de novo NAD(+) synthesis specifies immune function in  
513 aging and inflammation. *Nat Immunol* *20*, 50-63.
- 514 Murthy, S., Gomersall, C.D., and Fowler, R.A. (2020). Care for Critically Ill Patients With COVID-19.

- 515 JAMA.
- 516 Narasaraju, T., Yang, E., Samy, R.P., Ng, H.H., Poh, W.P., Liew, A.A., Phoon, M.C., van Rooijen, N.,  
517 and Chow, V.T. (2011). Excessive neutrophils and neutrophil extracellular traps contribute to acute  
518 lung injury of influenza pneumonitis. *Am J Pathol* *179*, 199-210.
- 519 Nie, S., Zhao, X., Zhao, K., Zhang, Z., Zhang, Z., and Zhang, Z. (2020). Metabolic disturbances and  
520 inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective  
521 study. medRxiv, 2020.2003.2024.20042283.
- 522 Pang, R.T., Poon, T.C., Chan, K.C., Lee, N.L., Chiu, R.W., Tong, Y.K., Chim, S.S., Sung, J.J., and Lo, Y.M.  
523 (2006). Serum amyloid A is not useful in the diagnosis of severe acute respiratory syndrome. *Clin*  
524 *Chem* *52*, 1202-1204.
- 525 Poon, T., Pang, R., Chan, K.C.A., Lee, N., Chiu, R., Tong, Y.-K., Chim, S., Ngai, S.M., Sung, J., and Lo,  
526 D. (2012). Proteomic analysis reveals platelet factor 4 and beta-thromboglobulin as prognostic  
527 markers in severe acute respiratory syndrome. *Electrophoresis* *33*, 1894-1900.
- 528 Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J.D. (2010). Complement: a key system for  
529 immune surveillance and homeostasis. *Nat Immunol* *11*, 785-797.
- 530 Rouzer, C.A., Ivanova, P.T., Byrne, M.O., Brown, H.A., and Marnett, L.J. (2007). Lipid profiling reveals  
531 glycerophospholipid remodeling in zymosan-stimulated macrophages. *Biochemistry* *46*, 6026-  
532 6042.
- 533 Rowland, A., Miners, J.O., and Mackenzie, P.I. (2013). The UDP-glucuronosyltransferases: Their role  
534 in drug metabolism and detoxification. *The International Journal of Biochemistry & Cell Biology*  
535 *45*, 1121-1132.
- 536 Russell, C.D., Millar, J.E., and Baillie, J.K. (2020). Clinical evidence does not support corticosteroid  
537 treatment for 2019-nCoV lung injury. *Lancet* *395*, 473-475.
- 538 Sanchez-Lopez, E., Zhong, Z., Stubelius, A., Sweeney, S.R., Booshehri, L.M., Antonucci, L., Liu-Bryan,  
539 R., Lodi, A., Terkeltaub, R., Lacal, J.C., *et al.* (2019). Choline Uptake and Metabolism Modulate  
540 Macrophage IL-1beta and IL-18 Production. *Cell Metab* *29*, 1350-1362 e1357.
- 541 Schoggins, J.W., and Randall, G. (2013). Lipids in innate antiviral defense. *Cell Host Microbe* *14*,  
542 379-385.
- 543 Sun, S., Zhao, G., Liu, C., Fan, W., Zhou, X., Zeng, L., Guo, Y., Kou, Z., Yu, H., Li, J., *et al.* (2014).  
544 Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African  
545 Green Monkeys. *Clinical Infectious Diseases* *60*, 586-595.
- 546 Sun, X., Song, L., Feng, S., Li, L., Yu, H., Wang, Q., Wang, X., Hou, Z., Li, X., Li, Y., *et al.* (2018). Fatty  
547 Acid Metabolism is Associated With Disease Severity After H7N9 Infection. *EBioMedicine* *33*, 218-  
548 229.
- 549 Team, T.N.C.P.E.R.E. (2020). The epidemiological characteristics of an outbreak of 2019 novel  
550 coronavirus diseases (COVID-19) in China. *41*, 145-151.
- 551 Thevarajan, I., Nguyen, T.H.O., Koutsakos, M., Druce, J., Caly, L., van de Sandt, C.E., Jia, X., Nicholson,  
552 S., Catton, M., Cowie, B., *et al.* (2020). Breadth of concomitant immune responses prior to patient  
553 recovery: a case report of non-severe COVID-19. *Nature Medicine*.
- 554 Vernon-Roberts, B. (1969). The effects of steroid hormones on macrophage activity. *Int Rev Cytol*  
555 *25*, 131-159.
- 556 Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., *et al.*  
557 (2020a). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected  
558 Pneumonia in Wuhan, China. *JAMA*.

### Molecular profiling of COVID-19 sera

- 559 Wang, R., Xiao, H., Guo, R., Li, Y., and Shen, B. (2015). The role of C5a in acute lung injury induced  
560 by highly pathogenic viral infections. *Emerg Microbes Infect* *4*, e28-e28.
- 561 Wang, T., Du, Z., Zhu, F., Cao, Z., An, Y., Gao, Y., and Jiang, B. (2020b). Comorbidities and multi-  
562 organ injuries in the treatment of COVID-19. *Lancet* *395*, e52.
- 563 Weigert, A., Weis, N., and Brune, B. (2009). Regulation of macrophage function by sphingosine-1-  
564 phosphate. *Immunobiology* *214*, 748-760.
- 565 Wilder-Smith, A., Earnest, A., and Paton, N.I. (2004). Use of simple laboratory features to  
566 distinguish the early stage of severe acute respiratory syndrome from dengue fever. *Clin Infect Dis*  
567 *39*, 1818-1823.
- 568 Wu, Z., and McGoogan, J.M. (2020). Characteristics of and Important Lessons From the Coronavirus  
569 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the  
570 Chinese Center for Disease Control and Prevention. *JAMA*.
- 571 Yan, B., Chu, H., Yang, D., Sze, K.-H., Lai, P.-M., Yuan, S., Shuai, H., Wang, Y., Kao, R.Y.-T., Chan,  
572 J.F.-W., *et al.* (2019). Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells:  
573 Implications for Lipid Metabolism Remodeling upon Coronavirus Replication. *Viruses* *11*, 73.
- 574 Zheng, Y., Zhang, Y., Chi, H., Chen, S., Peng, M., Luo, L., Chen, L., Li, J., Shen, B., and Wang, D.  
575 (2020). The hemocyte counts as a potential biomarker for predicting disease progression in  
576 COVID-19: a retrospective study. *CCLM clinical chemistry and laboratory medicine* *58*.
- 577 Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C., and  
578 Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-  
579 level datasets. *Nat Commun* *10*, 1523.
- 580 Zou, Z., Yang, Y., Chen, J., Xin, S., Zhang, W., Zhou, X., Mao, Y., Hu, L., Liu, D., Chang, B., *et al.* (2004).  
581 Prognostic factors for severe acute respiratory syndrome: a clinical analysis of 165 cases. *Clin Infect*  
582 *Dis* *38*, 483-489.
- 583
- 584
- 585

**Table 1. Demographics and baseline characteristics of COVID-19 patients.**

Variables	Healthy	non-COVID-	COVID-19		
	Control (N=28)	19 (N=25)	Total (N=46)	non-Severe (N=25)	Severe (N=21)
<b>Sex - no. <sup>a</sup> (%)</b>					
Male	21 (75.0)	17 (68.0)	31 (67.4)	18 (72.0)	13 (61.9)
Female	7 (25.0)	8 (32.0)	15 (32.6)	7 (28.0)	8 (38.1)
<b>Age - yr. <sup>b</sup></b>					
Mean ± SD	44.4±8.3	49.2±14.0	47.7±13.9	42.2±12.8	54.3±12.4
Median (IQR)	45.0 (38.0-51.0)	53.0 (37.0-61.0)	46.5 (35.8-59.0)	43.0 (33.0-50.0)	55.0 (47.0-63.0)
Range	28.0-57.0	23.0-67.0	20.0-75.0	20.0-70.0	30.0-75.0
<b>BMI, kg/m<sup>2</sup></b>					
Mean ± SD <sup>c</sup>	24.4±2.7	23.5±2.7	24.9±3.0	24.5±3.3	26.0±2.4
Median (IQR) <sup>d</sup>	24.2 (22.5-26.5)	24.7 (20.9-25.8)	24.8 (22.7-27.0)	24.9 (21.7-26.8)	25.8 (24.4-28.0)
Range	19.9-32.9	19.1-27.4	19.0-31.3	18.9-30.4	22.2-31.3
<b>Smoke - no. (%)</b>			5 (10.9)	2 (8.0)	1 (4.8)
<b>Alcohol - no. (%)</b>			1 (2.2)	1 (4.0)	0 (0.0)
<b>Time from onset to admission, days</b>					
Mean ± SD			3.0±4.2	1.6±2.1	4.6±5.4
Median (IQR)			1.5 (0.0-4.0)	1.0 (0.0-2.0)	2.0 (0.5-6.0)
Range			0.0-20.0	0.0-10.0	0.0-20.0
<b>Time from admission to severe, days</b>					
Mean ± SD					4.0±2.1
Median (IQR)					4.0 (2.5-5.5)
Range					0.0-7.0
<b>Symptoms - no. (%)</b>					
Fever		9 (36.0)	34 (73.9)	16 (64.0)	18 (85.7)
Cough		11 (44.0)	26 (56.5)	13 (52.0)	13 (61.9)
Headache		2 (8.0)	7 (15.2)	4 (16.0)	3 (14.3)
Fatigue		2 (8.0)	8 (17.4)	5 (20.0)	3 (14.3)
Pharyngalgia		0 (0.0)	3 (6.5)	1 (4.0)	2 (9.5)
Expectoration		3 (12.0)	12 (26.1)	4 (16.0)	8 (38.1)
Diarrhea		0 (0.0)	3 (6.5)	1 (4.0)	2 (9.5)
Chest tightness		2 (8.0)	1 (2.2)	1 (4.0)	0 (0.0)
<b>Chest CT <sup>e</sup> - no. (%)</b>					
Involvement of chest radiographs		1 (4.0)	45 (97.8)	24 (96.0)	21 (100)
<b>Comorbidity- no. (%)</b>					
Hypertension		10 (40.0)	6 (13.0)	1 (4.0)	5 (23.8)
Diabetes		0 (0.0)	6 (13.0)	3 (12.0)	3 (14.3)

## Molecular profiling of COVID-19 sera

Respiratory system	2 (8.0)	4 (8.7)	3 (12.0)	1 (4.8)
Endocrine system	0 (0.0)	3 (6.5)	0 (0.0)	3 (14.3)
Chronic kidney disease	0 (0.0)	1 (2.2)	0 (0.0)	1 (4.8)
Digestive system	2 (8.0)	6 (13.0)	3 (12.0)	3 (14.3)
<b>Oxygenation Index - mmHg</b>				
Mean ± SD			478.4±147.5	347.4±124.1
Median (IQR)			447.6	341.4
			(390.5-506.0)	(266.5-381.9)
Range			289.7-890.5	133.3-728.6
<b>Treatment - no. (%)</b>				
Oxygen inhalation	3 (12.0)	30 (65.2)	10 (40.0)	20 (95.2)
Antibiotics	0 (0.0)	15 (32.6)	8 (32.0)	7 (33.3)
Antiviral drug	25 (100)	46 (100.0)	25 (100.0)	21 (100.0)
Immunoglobulin	0 (0.0)	19 (41.3)	0 (0.0)	19 (90.5)
Methylprednisolone	0 (0.0)	16 (34.8)	0 (0.0)	16 (76.2)
Chinese medicine	0 (0.0)	45 (97.8)	25 (100.0)	20 (95.2)

588 <sup>a</sup> no. (%): number.

589 <sup>b</sup> yr.: year.

590 <sup>c</sup>SD: Standard Deviation.

591 <sup>d</sup> IQR: Interquartile range

592 <sup>e</sup> CT: Computed tomography

593



594 **Figure 1. Summary of COVID-19 patients and machine learning design.**  
595 (A) Summary of COVID-19 patients, including non-severe (n=25) and severe  
596 (n=21) patients with more details in Table S1. Patients labeled in red (Y-axis)  
597 indicate chronic infection of viruses including HBV. (B) Study design for  
598 machine learning-based classifier development for severe COVID-19 patients.  
599 We first procured samples in a training cohort for proteomic and metabolomic  
600 analysis. The classifier was then validated in an independent cohort.

601 **Figure 2. Separation of severe and non-severe COVID-19 patients by**  
602 **machine learning of proteomic and metabolomic features.** (A) Top 22  
603 proteins and 7 metabolites prioritized by random forest analysis ranked by the  
604 mean decrease in accuracy. (B) Network of prioritized proteins appeared in  
605 the classifier. (C) ROC of the random forest model in the training cohort. (D)  
606 Principal Components Analysis (PCA) plot of COVID-19 patients from the  
607 training cohort. (E) Performance of the model in the validation cohort of ten  
608 COVID-19 patients. Patients labeled in red received serum test before they  
609 were diagnosed as severe.

610 **Figure 3. Dysregulated proteins in COVID-19 sera.** (A) Heatmap of 50  
611 selected proteins whose regulation concentrated on three enriched pathways.  
612 (B) The expression level change (z-scored original value) of six selected  
613 proteins of interest with significance indicated by the asterisks (unpaired two  
614 sided Welch's t test. p value: \*\*\*, <0.001; \*\*, <0.01; \*, <0.05)

615 **Figure 4. Dysregulated metabolites in COVID-19 sera.** (A) Heatmap of 82  
616 regulated metabolites belonging to six major classes: fatty acids, steroids,  
617 glycerophospholipid, sphingolipid, choline and serotonins. (B) The expression  
618 level change (z-scored log2 original value) of six regulated metabolites from  
619 each metabolite class with significance indicated by the asterisks as  
620 described in Figure 3.

621 **Figure 5. Key proteins and metabolites characterized in severe COVID-**  
622 **19 patients in a working model.** SARS-CoV-2 may target alveolar  
623 macrophages via ACE2 receptor with increasing level of cytokines including  
624 IL-6 and TNF- $\alpha$ , which subsequently induce the elevation of various APPs  
625 such as SAP, CRP, SAA1, SAA2 and C6 which are significantly upregulated  
626 in the severe group. Proteins involved in macrophage, lipid metabolism and  
627 platelet degranulation were indicated with their corresponding expression  
628 levels in four patient groups.

629

## 630 **MATERIALS AND METHODS**

### 631 **Patients and samples**

632 Our team procured serum samples from 46 patients who visited Taizhou  
633 Public Health Medical Center during January 23 and February 4, 2020. They  
634 were diagnosed as COVID-19 according to the Chinese Government  
635 Diagnosis and Treatment Guideline (Trial 5th version)(Medicine, 2020). For  
636 diagnosing COVID-19, nucleic acid from sputum or throat swab was extracted  
637 using nucleic acid extractor (Shanghai Zhijiang, China, EX3600) and virus  
638 nucleic acid extraction reagent (Shanghai Zhijiang, China, NO. P20200201)  
639 was used to extract nucleic acid. Fluorescence quantitative PCR (ABI7500)  
640 and SARS-CoV-2 nucleic acid detection kit (triple fluorescence PCR,  
641 Shanghai Zhijiang, China, NO. P20200203) were used for nucleic acid  
642 detection. This kit uses one step RT-PCR combined with Taqman technology  
643 to detect RdRp, E and N genes. Positive was concluded if RdRp gene was  
644 positive (Ct < 43), and one of E or N was positive (Ct <43). Patients were also  
645 diagnosed as positive if two sequential tests of RdRp were positive while E  
646 and N were negative. According to the abovementioned guideline, COVID-19  
647 patients are classified into four subgroups: 1) Mild: mild symptoms without  
648 pneumonia; 2) Typical: fever or respiratory tract symptoms with pneumonia; 3)  
649 Severe: fulfill any of the three criteria: respiratory distress, respiratory rate  $\geq$   
650 30 times/min; means oxygen saturation  $\leq$  93% in resting state; arterial blood  
651 oxygen partial pressure/oxygen concentration  $\leq$  300 mmHg (1 mmHg = 0.133  
652 kPa); 4) Critical: fulfill any of the three criteria: respiratory failure and require  
653 mechanical ventilation; shock incidence; admission to ICU with other organ  
654 failure. In this study, we included both severe and no-severe patients, with the  
655 latter composed of mild and typical COVID-19 patients. Last follow-up of  
656 these patients was March 10, 2020. We also procured 25 non-COVID-19  
657 patients with similar clinical characteristics including fever and/or cough as  
658 COVID-19 patients however negative in the nucleic acid test. Based on the  
659 Chinese Government Diagnosis and Treatment Guideline (Trial 5th version)  
660 (Medicine, 2020), patients are defined as suspected COVID-19 cases when  
661 they meet the following three clinical criteria: 1) fever or respiratory symptoms,  
662 2) imaging manifestation of pneumonia, and 3) optional reduction of white  
663 blood cell or lymphocyte count at early stage. The patients only need to meet  
664 at least two of the above three criteria if they have been exposed to COVID-  
665 19 individuals. We also collected serum samples from 28 healthy individuals  
666 as control. All the serum samples were collected as venous whole blood in the  
667 early morning before diet using serum separation tubes (Zhejiang GongDong  
668 Medical Technology Co., Ltd, China). The blood samples were centrifuged at  
669 3,500 rpm for 10 min for serum collection. The serum samples were frozen at  
670  $-80^{\circ}\text{C}$ . The samples from this study is from a clinical trial that our team initiated  
671 and registered in the Chinese Clinical Trial Registry with a ID of  
672 ChiCTR2000031365. This study has been approved by the

673 Ethical/Institutional Review Board of Taizhou Public Health Medical Center  
674 and Westlake University. Contents from patients were waived by the boards.

675

### 676 **Proteomic analysis**

677 Serum samples were inactivated and sterilized at 56°C for 30 min, and  
678 processed as previously with some modifications. Five  $\mu\text{L}$  serum from each  
679 specimen was lysed in 50  $\mu\text{L}$  lysis buffer (8 M urea in 100 mM  
680 triethylammonium bicarbonate, TEAB) at 32°C for 30 min. The lysates were  
681 reductive with 10 mM tris (2-carboxyethyl) phosphine (TCEP) for 30 min at  
682 32°C, then alkylated for 45 min with 40 mM iodoacetamide (IAA) in darkness  
683 at room temperature (25°C). The protein extracts were diluted with 200  $\mu\text{L}$  100  
684 mM TEAB, and digested with double-step trypsinization (Hualishi Tech. Ltd,  
685 Beijing, China), each step with an enzyme-to-substrate ratio of 1:20, at 32°C  
686 for 60 min. The reaction was stopped by adding 30  $\mu\text{L}$  10% trifluoroacetic acid  
687 (TFA) in volume. Digested peptides were cleaned-up with SOLA $\mu$  (Thermo  
688 Fisher Scientific™, San Jose, USA) following the manufacturer's instructions,  
689 and labeled with TMTpro 16plex label reagents (Thermo Fisher Scientific™,  
690 San Jose, USA) as described previously. The TMT samples were fractionated  
691 using a nanoflow DIONEX UltiMate 3000 RSLCnano System (Thermo Fisher  
692 Scientific™, San Jose, USA) with an XBridge Peptide BEH C18 column (300  
693 Å, 5  $\mu\text{m}$   $\times$  4.6 mm  $\times$  250 mm) (Waters, Milford, MA, USA)(Gao et al., 2020).  
694 The samples were separated using a gradient from 5% to 35% acetonitrile  
695 (ACN) in 10 mM ammonia (pH=10.0) at a flow rate of 1 mL/min. Peptides  
696 were separated into 120 fractions, which were consolidated into 40 fractions.  
697 The fractions were subsequently dried and re-dissolved in 2% ACN/0.1%  
698 formic acid (FA). The re-dissolved peptides were analyzed by LC-MS/MS with  
699 the same LC system coupled to a Q Exactive HF-X hybrid Quadrupole-  
700 Orbitrap (Thermo Fisher Scientific™, San Jose, USA) in data dependent  
701 acquisition (DDA) mode. For each acquisition, peptides were loaded onto a  
702 precolumn (3  $\mu\text{m}$ , 100 Å, 20 mm $\times$ 75  $\mu\text{m}$  i.d.) at a flowrate of 6  $\mu\text{L}/\text{min}$  for 4 min  
703 and then injected using a 35 min LC gradient (from 5% to 28% buffer B) at a  
704 flowrate of 300 nL/min (analytical column, 1.9  $\mu\text{m}$ , 120 Å, 150 mm $\times$ 75  $\mu\text{m}$  i.d.).  
705 Buffer A was 2%ACN, 98% H<sub>2</sub>O containing 0.1% FA, and buffer B was 98%  
706 ACN, 2% H<sub>2</sub>O containing 0.1% FA. All reagents were MS grade. The  $m/z$   
707 range of MS1 was 350-1,800 with the resolution at 60,000 (at 200  $m/z$ ), AGC  
708 target of 3e6, and maximum ion injection time (max IT) of 50 ms. Top 15  
709 precursors were selected for MS/MS experiment, with a resolution at 45,000  
710 (at 200  $m/z$ ), AGC target of 2e5, and max IT of 120 ms. The isolation window  
711 of selected precursor was 0.7  $m/z$ . The resultant mass spectrometric data  
712 were analyzed using Proteome Discoverer (Version 2.4.1.15, Thermo Fisher  
713 Scientific) using a protein database composed of the *Homo sapiens* fasta  
714 database downloaded from UniprotKB on 07 Jan 2020 and the SARS-CoV-2  
715 virus fasta downloaded from NCBI (version NC\_045512.2). Enzyme was set  
716 to trypsin with two missed cleavage tolerance. Static modifications were set to

717 carbamidomethylation (+57.021464) of cysteine, TMTpro (+304.207145) of  
718 lysine residues and peptides' N termini, and variable modifications were set to  
719 oxidation (+15.994915) of methionine and acetylation (+42.010565) of  
720 peptides' N-termini. Precursor ion mass tolerance was set to 20 ppm, and  
721 product ion mass tolerance was set to 0.06 Da. The peptide-spectrum-match  
722 allowed 1% target false discovery rate (FDR) (strict) and 5% target FDR  
723 (relaxed). Normalization was performed against the total peptide amount. The  
724 other parameters followed the default setup.

725

### 726 **Quality control of proteomic data**

727 The quality of proteomic data was ensured at multiple levels. First, a mouse  
728 liver digest was used for instrument performance evaluation. We also run  
729 water samples (buffer A) as blanks every 4 injections to avoid carry-over.  
730 Serum samples of four patient groups from both training and validation  
731 cohorts were randomly distributed in eight different batches. Six samples were  
732 injected in technical replicates.

733

### 734 **Metabolomic analysis**

735 Ethanol was added to the serum samples and shaken vigorously to  
736 inactivate any potential viruses, then dried in a biosafety hood. The dried  
737 samples were further treated for metabolomics analysis. The metabolomic  
738 analysis was performed as described previously (Lee et al., 2019). Briefly,  
739 deactivated serum samples, 100  $\mu$ L each, were extracted by adding 300  $\mu$ L  
740 extraction solution. The mixtures were shaken vigorously for 2 min. Proteins  
741 were denatured and precipitated by centrifugation. The supernatants  
742 contained metabolites of diverse chemical natures. To ensure the quantity  
743 and reliability of metabolite detection, four platforms were performed with non-  
744 target metabolomics. Each supernatant was divided into four fractions: two for  
745 analysis using two separate reverse-phase /ultra-performance liquid  
746 chromatography (RP/UPLC)-MS/MS methods with positive ion-mode  
747 electrospray ionization (ESI), one for analysis using RP/ UPLC-MS/MS with  
748 negative-ion mode ESI, and one for analysis using hydrophilic interaction  
749 liquid chromatography (HILIC)/UPLC-MS/MS with negative-ion mode ESI.  
750 Each fraction was dried under nitrogen gas to remove the organic solvent and  
751 later re-dissolved in four different reconstitution solvents compatible with each  
752 of the four UPLC-MS/MS methods.

753 All UPLC-MS/MS methods used ACQUITY 2D UPLC system (Waters,  
754 Milford, MA, USA) and Q Exactive HF hybrid Quadrupole-Orbitrap (Thermo  
755 Fisher Scientific™, San Jose, USA) with HESI-II heated ESI source and  
756 Orbitrap mass analyzer. The mass spectrometer was operated at 35,000  
757 mass resolution (at 200  $m/z$ ). In the first UPLC-MS/MS method, the QE was  
758 operated under positive electron spray ionization (ESI) coupled with a C18  
759 column (UPLC BEH C18, 2.1  $\times$  100 mm, 1.7  $\mu$ m; Waters) was used in UPLC.  
760 The mobile solutions used in the gradient elution were water and methanol

761 containing 0.05% perfluoropentanoic acid (PFPA) and 0.1% FA. In the second  
762 method, the QE was still operated under ESI positive mode, and the UPLC  
763 used the same C18 column as in method one, but the mobile phase solutions  
764 were optimized for more hydrophobic compounds and contained methanol,  
765 acetonitrile, water, 0.05% PFPA, and 0.01% FA. The third method had the QE  
766 operated under negative ESI mode, and the UPLC method used a C18  
767 column eluted with mobile solutions containing methanol and water in 6.5 mM  
768 ammonium bicarbonate at pH 8. The UPLC column used in the fourth method  
769 was HILIC column (UPLC BEH Amide, 2.1 × 150 mm, 1.7 μm; Waters), and  
770 the mobile solutions were consisted of water and acetonitrile with 10 mM  
771 ammonium formate at pH 10.8; the QE was operated under negative ESI  
772 mode. The QE mass spectrometer analysis was alternated between MS and  
773 data-dependent MS2 scans using dynamic exclusion. The scan range was  
774 70-1,000 *m/z*.

775 After raw data pre-processing, peak finding/alignment, and peak  
776 annotation using in-house software, metabolites were identified by searching  
777 an in-house library containing more than 3,300 standards with library data  
778 entries generated from running purified compound standards through the  
779 experimental platforms. Identification of metabolites must meet three strict  
780 criteria: narrow window retention index (RI), accurate mass with variation less  
781 than 10 ppm and MS/MS spectra with high forward and reverse scores based  
782 on comparisons of the ions present in the experimental spectrum to the ions  
783 present in the library spectrum entries. Almost all isomers can be  
784 distinguished by these three criteria. All identified metabolites meet the level 1  
785 requirements by the Chemical Analysis Working Group (CAWG) of the  
786 Metabolomics Standards Initiative (MSI) expect some asterisk labeled lipids  
787 which MS/MS spectral were *in silico* matched.

788

### 789 **Quality control of metabolomics analysis**

790 Several types of quality control samples were included in the experiment:  
791 a pooled sample generated by taking a small volume of each experimental  
792 sample to serve as a technical replicate that was run multiple times  
793 throughout the experiment, extracted water samples served as blanks, and  
794 extracted commercial plasma samples for monitoring instrument variation. A  
795 mixture of internal standards was also spiked into every sample to aid  
796 chromatographic peak alignment and instrument stability monitoring.  
797 Instrument variability was determined by calculating the median relative SD  
798 (RSD) of all internal standards in each sample. The experimental process  
799 variability was determined by calculating the median RSD for all endogenous  
800 metabolites present in the pooled quality control samples.

801

### 802 **Statistical analysis**

803 Metabolites and therapeutic compounds with over 80% missing ratios in a  
804 particular patient group were removed for the metabolomics dataset

805 containing endogenous metabolites while full proteomics features were  
806 used for the subsequent statistical analysis. Missing values were imputed  
807 with the minimal value for each feature. Log<sub>2</sub> fold-change (log<sub>2</sub> FC) was  
808 calculated on the mean of the same patient group for each pair of comparing  
809 groups. Two-sided unpaired Welch's t test was performed for each pair of  
810 comparing groups and adjusted p values were calculated using Benjamini &  
811 Hochberg correction. The statistically significantly changed proteins or  
812 metabolites were selected using the criteria of adjusted p value less than 0.05  
813 indicated and absolute log<sub>2</sub> FC larger than 0.25. From the training cohort, the  
814 important features were selected with mean decrease accuracy larger than 3  
815 using random forest containing a thousand trees using R package  
816 randomForest (version 4.6.14) random forest analysis with 10-fold cross  
817 validation as binary classification of paired severe and non-severe group  
818 using combined differentially regulated proteins and metabolites features. The  
819 random forest analysis was further performed for a hundred times on the  
820 matrix with only the selected important features using normalized additive  
821 predicting probability as the final predicting probability and the larger  
822 probability as the predictive label. Those selected important features were  
823 used for the random forest analysis on the independent validation cohort.

824

### 825 **Pathway analysis**

826 Four network pathway analysis tools were used for pathway analysis using 93  
827 differentially expressed proteins (DEPs). The top Gene Ontology (GO)  
828 processes were enriched by Metascape web-based platform (Zhou et al.,  
829 2019). The GO terms is enriched using the Cytoscape plug-in ClueGO  
830 (Bindea et al., 2009). Ingenuity pathway analysis (Kramer et al., 2014) of the  
831 regulated proteins identifies most significantly relevant pathways with p value  
832 of determined based on right-tailed Fisher's Exact Test with the overall  
833 activation or inhibition states of enriched pathways were predicted by z-score.  
834 Functional co-expression network analysis by GeNet(Li et al., 2018a) to  
835 represent statistical co-expressed protein modules.

836

837 **Figure S1. Quality control of proteomic and metabolomic data.** (A)  
838 Coefficient of variation (CV) of the proteomic data is calculated by the proteins  
839 quantified in six quality control (QC) samples using the pooled samples from  
840 all samples in training cohort. CV of the metabolomic data is calculated by  
841 twelve QC samples using a set of isotopic internal spiked-in standards. (B)  
842 UMAP of sera samples using 791 measured proteins. (C) UMAP of sera  
843 samples using 847 metabolites.

844 **Figure S2. Differentially expressed proteins in different patient groups in  
845 the training cohort.** Volcano plots compare four pairs of patient groups as  
846 indicated in the plot. Proteins with  $\log_2$  (fold-change) beyond 0.25 or below -  
847 0.25 with adjusted p value lower than 0.05 were considered as significantly  
848 differential expression. Number of significantly down- (blue) and up- (red)  
849 regulated proteins were shown on the top.


850 **Figure S3. Differentially expressed metabolites in different patient  
851 groups in the training cohort.** The volcano plots follow that for Figure S3  
852 except metabolomic data were used as the input.

853 **Figure S4. Proteins and metabolites regulated in COVID-19 patients but  
854 not in non-COVID-19 patients.** Venn diagrams showing the overlaps  
855 between significantly regulated proteins (A) and metabolites (B) as identified  
856 in volcano plots. Proteins and metabolites labeled in red are the shortlisted  
857 molecules which differentially expressed in the COVID-19 patients but not in  
858 the non-COVID-19 patients.

859 **Figure S5. Identification of specific clusters of proteins and metabolites  
860 in COVID-19 patients.** 791 proteins (A) and 941 metabolites (B) were  
861 clustered using mFuzz into 16 significant discrete clusters, respectively, to  
862 illustrate the relative expression changes of the proteomics and metabolomics  
863 data. The groups in proteomics data: 1: Healthy; 2: non-Severe COVID-19; 3:  
864 Severe COVID-19. The groups in metabolomics data: 1: Healthy; 2: non-  
865 COVID-19; 3: non-Severe COVID-19; 4: Severe COVID-19.

866 **Figure S6. Pathway analysis of 93 differential expressed proteins in  
867 COVID-19 patients.** (A) The Gene Ontology (GO) processes enriched by  
868 Metascape. (B) The GO terms enriched using the Cytoscape plug-in ClueGO.  
869 (C) Ingenuity pathway analysis of most significantly relevant pathways with  
870 the predicted activation or inhibition state. (D) Functional network analysis by  
871 GeNet identifies several communities.

Figure 1



**B**






Figure 2




Figure 3





Figure 4

**A**



**B**




Figure 5






Figure S1

**A**



**B**



**C**




Figure S2







Figure S3








Figure S4

**A**



**B**







Figure S5

**A**



**B**




Figure S6

